Booz Allen Hamilton EVP & general counsel sells $124,380 in stock

Booz Allen General Counsel Joshua Petty sold 1,500 Class A shares for $124,380 on October 28, 2026, at $82.92 per share; his reported direct beneficial ownership afterward was 8,538 shares. Separately, fiscal Q2 adjusted EPS of $1.76 beat the $1.48 estimate, while revenue of $2.8B fell 3.9% year over year and slightly missed forecasts; free cash flow was $263M and backlog nearly $41B. Analyst views diverged, with UBS and TD Cowen raising price targets to $86 and $95, respectively, while BofA cut its target to $68.

Analysis

The key signal is the quality of backlog conversion, not the insider sale or headline EPS beat. A tax-rate benefit can lift adjusted earnings without improving core economics; meanwhile, declining revenue makes funded backlog conversion and new awards the near-term tests. The increase in funded backlog is more decision-useful than total backlog, but neither establishes when revenue will materialize or at what margin. A federal budget delay, cancellations, or slower procurement would extend that conversion risk and could pressure BAH before total backlog visibly rolls off.

Petty’s sale is small relative to his reported remaining direct ownership, which includes unvested RSUs; on its own it is weak evidence of deteriorating prospects. The shift to quarterly vesting changes liquidity timing, not the underlying award’s three-year service condition. More broadly, a renewed focus on funded work and delivery could favor scaled government-services peers such as CACI, Leidos, and SAIC if BAH’s civilian growth or revenue conversion lags, though this article provides no comparative operating data to justify a pair trade.

Near term, the 13% weekly rally and mixed analyst targets leave asymmetric disappointment risk if the next update shows another revenue decline or funded-backlog weakness. Over 1–3 months, monitor federal award timing, funded backlog, revenue growth, and whether EPS strength persists excluding tax effects. Over 6–18 months, sustained conversion would validate backlog quality; continued revenue contraction would undermine it. The article’s stated November 6 vesting is after the current October 31 date, and its quoted price/return timing should be verified before trading. The undervaluation claim is not independently supported here.

Key Decisions for Investors

• No trade on the isolated 1,500-share sale. Treat it as low-signal unless subsequent filings show repeated, materially larger insider sales or ownership reductions beyond scheduled vesting.
• Avoid chasing BAH after the sharp weekly rise. Set an alert for the next results or guidance update: sustained revenue contraction, weaker funded backlog, or EPS growth dependent on tax effects would support a cautious/short bias; improving revenue and funded-backlog conversion would falsify it.
• If seeking relative exposure, compare BAH with CACI, Leidos, and SAIC only after checking comparable revenue growth, award timing, and valuation; the supplied information is insufficient to recommend a pair trade.
• Verify the article’s as-of price and future-dated vesting reference, then track federal budget and procurement developments as catalysts that could delay backlog conversion.